Clive Wilder-Smith

Summary

Affiliation: Gastroenterology Group Practice
Country: Switzerland

Publications

  1. ncbi request reprint Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers
    Clive H Wilder-Smith
    Gastrointestinal Unit and Gastrointestinal Physiology Laboratory, Bern, Switzerland
    Digestion 68:184-8. 2003
  2. ncbi request reprint Morphometric quantification of normal submucous plexus in the distal rectum of adult healthy volunteers
    Clive H Wilder-Smith
    Gastroenterology Group Practice, Bern, Switzerland
    Eur J Gastroenterol Hepatol 14:1339-42. 2002
  3. ncbi request reprint Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study
    C H Wilder-Smith
    Gastroenterology Group Practice, GI Physiology Laboratory, Berne, Switzerland
    Aliment Pharmacol Ther 20:1099-104. 2004
  4. ncbi request reprint Photoeradication of Helicobacter pylori using 5-aminolevulinic acid: preliminary human studies
    Clive H Wilder-Smith
    Gastrointestinal Group Practice and Nociception Research Group, Bubenbergplatz 11, CH 3011 Berne, Switzerland
    Lasers Surg Med 31:18-22. 2002
  5. pmc Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls
    C H Wilder-Smith
    Brain Gut Research Group, Bubenbergplatz 11, CH 3011 Berne, Switzerland
    Gut 53:1595-601. 2004
  6. ncbi request reprint Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies
    Clive H Wilder-Smith
    GI Physiology Laboratory, Bern, Switzerland
    Eur J Gastroenterol Hepatol 17:191-7. 2005
  7. ncbi request reprint Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study
    Clive Wilder-Smith
    Brain Gut Research Group, Gastroenterology Group Practice, Berne, Switzerland
    Clin Drug Investig 28:333-43. 2008
  8. ncbi request reprint Acid control with esomeprazole and lansoprazole: a comparative dose-response study
    Clive Wilder-Smith
    Brain Gut Research Group, Gastroenterology Group Practice, Berne, Switzerland
    Scand J Gastroenterol 42:157-64. 2007
  9. ncbi request reprint Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Kerstin Röhss
    Experimental Medicine, AstraZeneca R and D Molndal, Pepparedsleden 1, 431 83, Molndal, Sweden
    Eur J Clin Pharmacol 60:531-9. 2004

Detail Information

Publications9

  1. ncbi request reprint Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers
    Clive H Wilder-Smith
    Gastrointestinal Unit and Gastrointestinal Physiology Laboratory, Bern, Switzerland
    Digestion 68:184-8. 2003
    ..To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers...
  2. ncbi request reprint Morphometric quantification of normal submucous plexus in the distal rectum of adult healthy volunteers
    Clive H Wilder-Smith
    Gastroenterology Group Practice, Bern, Switzerland
    Eur J Gastroenterol Hepatol 14:1339-42. 2002
    ..The internal submucous plexus (Meissner plexus) was morphometrically quantified in adult healthy volunteers...
  3. ncbi request reprint Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study
    C H Wilder-Smith
    Gastroenterology Group Practice, GI Physiology Laboratory, Berne, Switzerland
    Aliment Pharmacol Ther 20:1099-104. 2004
    ..Oral esomeprazole 40 mg provides greater acid control than oral pantoprazole 40 mg...
  4. ncbi request reprint Photoeradication of Helicobacter pylori using 5-aminolevulinic acid: preliminary human studies
    Clive H Wilder-Smith
    Gastrointestinal Group Practice and Nociception Research Group, Bubenbergplatz 11, CH 3011 Berne, Switzerland
    Lasers Surg Med 31:18-22. 2002
    ..These first human in vivo studies investigated the photoeradication of HP using laser and white light...
  5. pmc Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls
    C H Wilder-Smith
    Brain Gut Research Group, Bubenbergplatz 11, CH 3011 Berne, Switzerland
    Gut 53:1595-601. 2004
    ..Abnormalities in endogenous pain inhibitory mechanisms, such as diffuse noxious inhibitory controls (DNIC), may be implicated and were investigated during brain functional magnetic resonance imaging (fMRI)...
  6. ncbi request reprint Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies
    Clive H Wilder-Smith
    GI Physiology Laboratory, Bern, Switzerland
    Eur J Gastroenterol Hepatol 17:191-7. 2005
    ..Two studies compared the effects of intravenous (i.v.) and oral esomeprazole (40 mg and 20 mg) on gastric acid suppression and pharmacokinetics after both single (day 1) and repeated (day 5) dosing...
  7. ncbi request reprint Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study
    Clive Wilder-Smith
    Brain Gut Research Group, Gastroenterology Group Practice, Berne, Switzerland
    Clin Drug Investig 28:333-43. 2008
    ....
  8. ncbi request reprint Acid control with esomeprazole and lansoprazole: a comparative dose-response study
    Clive Wilder-Smith
    Brain Gut Research Group, Gastroenterology Group Practice, Berne, Switzerland
    Scand J Gastroenterol 42:157-64. 2007
    ..These data are relevant in helping clinicians to decide on whether to increase a proton-pump inhibitor dose, or whether to switch to an alterative drug for increased acid control...
  9. ncbi request reprint Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Kerstin Röhss
    Experimental Medicine, AstraZeneca R and D Molndal, Pepparedsleden 1, 431 83, Molndal, Sweden
    Eur J Clin Pharmacol 60:531-9. 2004
    ....